Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP)

Launched by HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID · Feb 13, 2024

Keywords

ClinConnect Summary

The TRIDIGEP study is looking into how well new migraine medications work and how well people tolerate them during regular treatment. This study focuses on three types of medications: Triptans, Gepants, and Ditans, which are used to relieve migraine attacks. Researchers want to understand how effective these treatments are in real-life situations, how well people can handle them, and if certain factors can predict how well someone might respond to these medications. Participants in the study will use a simple online tool to share their experiences and track their symptoms after taking the medications.

To join the study, participants should be adults aged 18 and older who have been diagnosed with migraines and are currently using one of the studied medications as directed by their doctor. They also need access to a smartphone, tablet, or computer with the internet and must agree to participate by signing a consent form. People with certain conditions, like using other strong pain medications or having serious cognitive issues, won’t be eligible. The study is currently recruiting participants, and by taking part, individuals can help contribute to better understanding and treatment of migraines.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fulfill the criteria for migraine, according to the International Classification of Headache Disorders, 3rd version;
• • Treatment with triptans, Lasmiditan or Gepants as acute therapies according to their responsible physician criteria under routine clinical practice criteria;
• • Participant have a smartphone, tablet, or computer with an internet connection;
• • Participant accept to participate and sign the informed consent form
• Exclusion Criteria:
• • Patient have a concomitant use of opioids, barbiturates, or ergot derivates;
• • Participant have major cognitive or psychiatric disorder;
• • Participants are unable to describe the result of the employed drug
• • Participants have an insufficient proficiency of the local languages.